ReviewEndocrine reviews2020
Glycemic Monitoring and Management in Advanced Chronic Kidney Disease.
Review in Endocrine reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06069518 (Continuous Glucose Monitoring as a Strategy to Optimize Metabolic Control in Patients With Diabetes on Peritoneal Dialysis Therapy Entitled to the IMSS), which is not on this map. Cited by 113 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Continuous Glucose Monitoring as a Strategy to Optimize Metabolic Control in Patients With Diabetes on Peritoneal Dialysis Therapy Entitled to the IMSS
Who cites it
113 citing papers in PubMed, 2 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Closed-Loop Automated Insulin Delivery in Patients With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials.Endocrinology, diabetes & metabolism · 2026Pooled it
- Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline.Journal of diabetes science and technology · 2020Guideline
- Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.Diabetes care · 2026Trial
- The impact of automated insulin delivery on glucose management in people with diabetes and advanced chronic kidney disease.Diabetologia · 2026Trial
- Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease.World journal of clinical cases · 2022Trial
- Person-Reported and Continuous Glucose Monitoring (CGM) Recorded Hypoglycaemia in People With Insulin-Treated Type 2 Diabetes and Mild to Moderate Chronic Kidney Disease; Post Hoc Analysis From the Hypo-METRICS Study.Diabetes, obesity & metabolism · 2026Observational
- Stress hyperglycemia ratio as a predictor of in-hospital mortality in patients with acute kidney injury: a retrospective cohort study.Clinical and experimental nephrology · 2026Article
- Correlation Between Glycemic Biomarkers and Continuous Glucose Monitoring Metrics in Chronic Kidney Disease: A Systematic Review and Correlation Meta-Analysis.Journal of clinical medicine · 2026Review
- Glycemic instability in renal decline: a review of HbA1c variability and outcomes in chronic kidney disease.Diabetology & metabolic syndrome · 2026Review
- Glycemic Patterns Revealed by Continuous Glucose Monitoring in Patients with Type 2 Diabetes Undergoing Intermittent Hemodialysis: A Pilot Study.Medical sciences (Basel, Switzerland) · 2026Observational
- Development and evaluation of a clinical dashboard for nephrology inpatients: a pilot study.BMC medical informatics and decision making · 2026Article
- Role of automated insulin delivery (AID) systems in glucose control in patients with diabetes mellitus undergoing dialysis in Calabria: AID-DIAL-CAL.Acta diabetologica · 2026Article
- Accuracy, Variability, and Bias of Glycemic Biomarkers in Patients Treated With Maintenance Dialysis.Diabetes care · 2026Article
- Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin's Therapeutic Potential in Chronic Kidney Disease.Life (Basel, Switzerland) · 2026Article
- Glycemic control targets in older adults with type 2 diabetes and chronic kidney disease: a trajectory-based survival analysis of glycated hemoglobin.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Endocrine disorders linked to chronic kidney disease: Mechanisms and clinical implications.World journal of nephrology · 2026Review
- Continuous glucose monitoring (CGM) use in people living with diabetes on maintenance dialysis: a retrospective audit and observational cohort study.BMC nephrology · 2026Observational
- Sex-specific threshold effect of albumin-corrected fructosamine on diabetic retinopathy: a nonlinear relationship in women but linear in men - a cross-sectional study.Frontiers in endocrinology · 2026Article
- Urinary tract infections in diabetes: clinical significance and management approaches.Acta biochimica Polonica · 2026Review
- Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Glucose and insulin metabolism in patients with diabetes are profoundly altered by advanced chronic kidney disease (CKD). Risk of hypoglycemia is increased by failure of kidney gluconeogenesis, impaired insulin clearance by the kidney, defective insulin degradation due to uremia, increased erythrocyte glucose uptake during hemodialysis, impaired counterregulatory hormone responses (cortisol, growth hormone), nutritional deprivation, and variability of exposure to oral antihyperglycemic agents and exogenous insulin. Patients with end-stage kidney disease frequently experience wide glycemic excursions, with common occurrences of both hypoglycemia and hyperglycemia. Assessment of glycemia by glycated hemoglobin (HbA1c) is hampered by a variety of CKD-associated conditions that can bias the measure either to the low or high range. Alternative glycemic biomarkers, such as glycated albumin or fructosamine, are not fully validated. Therefore, HbA1c remains the preferred glycemic biomarker despite its limitations. Based on observational data for associations with mortality and risks of hypoglycemia with intensive glycemic control regimens in advanced CKD, an HbA1c range of 7% to 8% appears to be the most favorable. Emerging data on the use of continuous glucose monitoring in this population suggest promise for more precise monitoring and treatment adjustments to permit fine-tuning of glycemic management in patients with diabetes and advanced CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.